Kinetics Of Chronic Lymphocytic Leukemia Cells In Tissues and Blood During Therapy With The BTK Inhibitor Ibrutinib
Wodarz D, Garg N, Komarova N et al.
Key Points:
Study goal: to better characterize dynamics of lymphocytes redistribution phenomenon caused by ibrutinib treated patients with CLL.
Findings: ibrutinib therapy, 1.7 ± 1.1% of the cells die per day in the blood, while in tissue 2.7% ± 0.99% of the cells die per day.
Rate approximately 5 times higher during the treatment with ibrutinib.
Authors demonstrated that relatively small fraction of total tissue CLL cell burden re-distributed into blood during therapy with ibrutinib, and that significant amount of drug-induced cell death occurs in tissue.
Implications:
- Relatively small fraction of total tissue CLL cell burden re-distributed into blood during the therapy with ibrutinib.
View the original abstract on the ASH website.
